BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Frémond ML, Crow YJ. STING-Mediated Lung Inflammation and Beyond. J Clin Immunol 2021;41:501-14. [PMID: 33532887 DOI: 10.1007/s10875-021-00974-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Vila IK, Guha S, Kalucka J, Olagnier D, Laguette N. Alternative pathways driven by STING: From innate immunity to lipid metabolism. Cytokine & Growth Factor Reviews 2022. [DOI: 10.1016/j.cytogfr.2022.08.006] [Reference Citation Analysis]
2 Skopelja-Gardner S, An J, Elkon KB. Role of the cGAS-STING pathway in systemic and organ-specific diseases. Nat Rev Nephrol 2022. [PMID: 35732833 DOI: 10.1038/s41581-022-00589-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Beck DB, Werner A, Kastner DL, Aksentijevich I. Disorders of ubiquitylation: unchained inflammation. Nat Rev Rheumatol 2022. [PMID: 35523963 DOI: 10.1038/s41584-022-00778-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
4 Tanaka T, Shiba T, Honda Y, Izawa K, Yasumi T, Saito MK, Nishikomori R. Induced Pluripotent Stem Cell-Derived Monocytes/Macrophages in Autoinflammatory Diseases. Front Immunol 2022;13:870535. [DOI: 10.3389/fimmu.2022.870535] [Reference Citation Analysis]
5 Cetin Gedik K, Lamot L, Romano M, Demirkaya E, Piskin D, Torreggiani S, Adang LA, Armangue T, Barchus K, Cordova DR, Crow YJ, Dale RC, Durrant KL, Eleftheriou D, Fazzi EM, Gattorno M, Gavazzi F, Hanson EP, Lee-Kirsch MA, Montealegre Sanchez GA, Neven B, Orcesi S, Ozen S, Poli MC, Schumacher E, Tonduti D, Uss K, Aletaha D, Feldman BM, Vanderver A, Brogan PA, Goldbach-Mansky R. The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology Points to Consider for Diagnosis and Management of Autoinflammatory Type I Interferonopathies: CANDLE/PRAAS, SAVI, and AGS. Arthritis Rheumatol 2022;74:735-51. [PMID: 35315249 DOI: 10.1002/art.42087] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 David C, Frémond ML. [When to consider type I interferonopathy in adulthood?]. Rev Med Interne 2022:S0248-8663(21)01114-0. [PMID: 35177256 DOI: 10.1016/j.revmed.2021.11.003] [Reference Citation Analysis]
7 Cetin Gedik K, Lamot L, Romano M, Demirkaya E, Piskin D, Torreggiani S, Adang LA, Armangue T, Barchus K, Cordova DR, Crow YJ, Dale RC, Durrant KL, Eleftheriou D, Fazzi EM, Gattorno M, Gavazzi F, Hanson EP, Lee-Kirsch MA, Montealegre Sanchez GA, Neven B, Orcesi S, Ozen S, Poli MC, Schumacher E, Tonduti D, Uss K, Aletaha D, Feldman BM, Vanderver A, Brogan PA, Goldbach-Mansky R. The 2021 EULAR and ACR points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and AGS. Ann Rheum Dis 2022:annrheumdis-2021-221814. [PMID: 35086813 DOI: 10.1136/annrheumdis-2021-221814] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
8 Lindahl H, Bryceson YT. Neuroinflammation Associated With Inborn Errors of Immunity. Front Immunol 2022;12:827815. [DOI: 10.3389/fimmu.2021.827815] [Reference Citation Analysis]
9 David C, Frémond M. Lung Inflammation in STING-Associated Vasculopathy with Onset in Infancy (SAVI). Cells 2022;11:318. [DOI: 10.3390/cells11030318] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
10 Bondet V, Le Baut M, Le Poder S, Lécu A, Petit T, Wedlarski R, Duffy D, Le Roux D. Constitutive IFNα Protein Production in Bats. Front Immunol 2021;12:735866. [PMID: 34790193 DOI: 10.3389/fimmu.2021.735866] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
11 Crow YJ, Stetson DB. The type I interferonopathies: 10 years on. Nat Rev Immunol 2021. [PMID: 34671122 DOI: 10.1038/s41577-021-00633-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 29] [Article Influence: 1.0] [Reference Citation Analysis]
12 Hadjadj J, Frémond ML, Neven B. Emerging Place of JAK Inhibitors in the Treatment of Inborn Errors of Immunity. Front Immunol 2021;12:717388. [PMID: 34603291 DOI: 10.3389/fimmu.2021.717388] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
13 Ye G, Zhang J, Zhang C. Stimulator of interferon response cGAMP interactor overcomes ERBB2-mediated apatinib resistance in head and neck squamous cell carcinoma. Aging (Albany NY) 2021;13:20793-807. [PMID: 34459788 DOI: 10.18632/aging.203475] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Ochfeld E, Curran ML, Chiarella SE, Ardalan K, Khojah A. A Case Report of SAVI Mimicking Early-Onset ANCA Vasculitis. J Clin Immunol 2021. [PMID: 34089458 DOI: 10.1007/s10875-021-01072-w] [Reference Citation Analysis]
15 Aksentijevich I, Schnappauf O. Molecular mechanisms of phenotypic variability in monogenic autoinflammatory diseases. Nat Rev Rheumatol 2021;17:405-25. [PMID: 34035534 DOI: 10.1038/s41584-021-00614-1] [Cited by in F6Publishing: 6] [Reference Citation Analysis]